From notes@igc.apc.org Wed Dec 28 11:30:02 1994 Date: 28 Dec 1994 05:56:23 Reply-To: Conference "aidstreatment" From: chrein@aol.com Subject: Crypto Drug Enters Phase II To: Recipients of conference Reply-To: chrein@aol.com (Chrein) I thought the following would be of interest to your list readers: PHASE II CLINICAL TRIALS TO BEGIN ON Cryptosporidiosis Drug Biomune Systems, Inc., announced in early December that it has entered into a contractual agreement with Professor Donald P. Kotler, M.D., of Columbia University, and with St. Luke's Roosevelt Hospital in New York City to begin Phase II clinical studies of Immuno-C, a protein antibody biologic product for the treatment of Cryptosporidiosis. Dr. Kotler is a leading international expert in gastroenterology and AIDS, specializing in AIDS-related Cryptosporidiosis. This disease is fatal in many cases to immunocompromised individuals, and is classified by the National Centers for Disease Control as a rapidly emerging infectious disease. Biomune Systems, Inc. is a biotechnology company engaged in the research and development of a biologic immune technology for the treatment of human Cryptosporidiosis. For more information, please contact Lloyd Chrein at chrein@aol.com.